Psyence Biomedical EBITDA TCAC 3A

Que fait Psyence Biomedical ? Psyence Biomedical Ltd, a Canadian company headquartered in Toronto, Ontario, completed its initial public offering (IPO) on December 10, 2021. The company operates in the healthcare sector, focusing on the development of natural psilocybin products aimed at addressing psychological trauma and its mental health consequences within palliative care. Psyence Biomedical has entered into a partnership with iNGENu Pty Ltd, an Australia-based contract research organization (CRO) specializing in psychedelic pharmaceutical drug development and clinical research. This collaboration supports the company's Phase IIb clinical trial, which utilizes PEX010, a 25mg naturally derived psilocybin drug candidate product. The drug candidate was in-licensed by Psyence Biomedical for this specific trial. The company's website is listed as http://psyence.com, providing further information about its operations and initiatives. Psyence Biomedical does not specify its industry or sector beyond healthcare, and it remains focused on advancing its clinical research in the field of psychedelic-assisted therapy for palliative care settings. The company's activities are centered around developing natural psilocybin-based treatments, with an emphasis on clinical trials to validate their efficacy and safety in palliative care contexts. Psyence Biomedical's strategic partnership with iNGENu highlights its engagement with global expertise in the psychedelic pharmaceutical sector. The company's IPO in 2021 marks a significant milestone in its journey toward commercializing its therapeutic approaches. Psyence Biomedical est l'une des entreprises les plus populaires sur Eulerpool.